Clinical consensus and associated costs to diagnose and treat genital warts caused by Human Papilloma virus in Ecuador- Results of a panel of experts
Author(s)
Roldos MI1, Bustamante V1, Monsanto H2
1Universidad San Francisco de Quito, Quito, Ecuador, 2Merck Sharp & Dohme IA LLC, Carolina, PR, PR
Presentation Documents
OBJECTIVES: Decision-makers used economic evaluations to allocate resources, prioritize programs or minimize costs. Panels of experts are one of the methods used by economic evaluators to gather the necessary information to construct models, such as the Delphi technique. Given the limitations of the surveillance of STDs in Ecuador, it is not surprising that no data is available of the disease burden to diagnose and treat diseases caused by HPV. METHODS: The main objective of the study is to reach a consensus of the local clinical practices in the diagnosis and treatment of genital warts caused by HPV and the market-based costs of medical specialists' time, resources, and medical supplies from a societal perspective. RESULTS: The diagnostic method of preference of medical specialists in Ecuador is the vulvar colposcopy followed by the biopsy with a histopathology study. Medical specialists prefer to use pharmacological treatments to resolve the presence of genital warts using Trichloroacetic acid (TCA). Surgical treatment was not favored by panelists. The cost per patient to diagnose and treat is between $395 and $484 USD per patient. The biggest variation is dependent on the price of medical consultations and the frequency of visits depending of the treatment path offered. CONCLUSIONS: The prevention of genital warts caused by HPV has the fundamental purpose to alleviate the morbidity of days lost from disability and the societal economic burden of its treatment. Preventive vaccination can prevent the morbidity burden of genital warts plus the potential of precancers and cancers.
Conference/Value in Health Info
2015-09, ISPOR Latin America 2015, Santiago, Chile
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PIH8
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine), Reproductive and Sexual Health